An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma

References

• Sirohi B, Powles R. Multiple myeloma. Lancet 2004; 363: 875–887
   PubMed Web of Science ®Google Scholar
• Ferlay J, Bray F, Pisani P, Parkin D M. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARCPress, LyonFrance 2004, IARC CancerBase No. 5. version 2.0 Available online at: http://www-dep.iarc.fr/, accessed 15 August 2006
   Google Scholar
• Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, et al. Treatment of multiple myeloma. Blood 2004; 103: 20–32
   PubMed Web of Science ®Google Scholar
• Harousseau J L, Shaughnessy J, Jr, Richardson P. Multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2004; 237–256
   PubMedGoogle Scholar
• Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123
   PubMed Web of Science ®Google Scholar
• Mileshkin L R, Seymour J F, Wolf M M, Gates P, Januszewicz E H, Joyce P, Prince H M. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma 2005; 46: 1575–1579
   PubMed Web of Science ®Google Scholar
• Multiple Myeloma: The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, version 1. 2005. National Comprehensive Cancer Network, Jenkintown, PA, Available online at: http://www.nccn.org/, accessed 15 August 2006
   Google Scholar
• Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825–831
   PubMed Web of Science ®Google Scholar
• Dimopoulos M A, Spencer A, Attal M, Prince M, Harousseau J L, Dmoszynska A, et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010) [abstract]. Blood 2005; 106: 6a–7a
   Google Scholar
• Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Bortezomib continues demonstrates superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: updated results of the APEX Trial [abstract]. Blood 2005; 106: 715a–716a
   Web of Science ®Google Scholar
• Franks M E, Macpherson G R, Figg W D. Thalidomide. Lancet 2004; 363: 1802–1811
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
   PubMed Web of Science ®Google Scholar
• Matthews S J, McCoy C. Thalidomide: a review of approved and investigational uses. Clin Ther 2003; 25: 342–395
   PubMed Web of Science ®Google Scholar
• Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132: 584–593
   PubMed Web of Science ®Google Scholar
• Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492–494
   PubMed Web of Science ®Google Scholar
• Hus M, Dmoszynska A, Soroka-Wojtaszko M, Jawniak D, Legiec W, Ciepnuch H, et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001; 86: 404–408
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Biagi J J, Mitchell P, Underhill C, Grigg A, Bell R, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003; 102: 69–77
   PubMed Web of Science ®Google Scholar
• Schey S A, Cavenagh J, Johnson R, Child J A, Oakervee H, Jones R W. A UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res 2003; 27: 909–914
   PubMed Web of Science ®Google Scholar
• Tosi P, Zamagni E, Cellini C, Ronconi S, Patriarca F, Ballerini F, et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002; 87: 408–414
   PubMed Web of Science ®Google Scholar
• Waage A, Gimsing P, Juliusson G, Turesson I, Gulbrandsen N, Eriksson T, et al. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br J Haematol 2004; 125: 149–155
   PubMed Web of Science ®Google Scholar
• Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C, et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients—report of the intergroupe francophone du myélome (IFM). Hematol J 2002; 3: 185–192
   PubMedGoogle Scholar
• Huang S Y, Tang J L, Yao M, Ko B S, Hong R L, Tsai W, et al. Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma. Ann Hematol 2003; 82: 558–564
   PubMed Web of Science ®Google Scholar
• Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho A D, et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002; 8: 3377–3382
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188
   PubMed Web of Science ®Google Scholar
• Cavenagh J D, Oakervee H. Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol 2003; 120: 18–26
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Prince H M. The adverse prognostic impact of advanced age in multiple myeloma. Leuk Lymphoma 2005; 46: 951–966
   PubMed Web of Science ®Google Scholar
• Dimopoulos M A, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004; 117: 508–515
   PubMed Web of Science ®Google Scholar
• Weber D. Thalidomide and its derivatives: new promise for multiple myeloma. Cancer Control 2003; 10: 375–383
   PubMedGoogle Scholar
• Lee F C. Second response to lower-dose thalidomide in a patient with multiple myeloma [letter]. Blood 2002; 99: 4248
   PubMed Web of Science ®Google Scholar
• Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004; 79: 875–882
   PubMed Web of Science ®Google Scholar
• Tosi P, Zamagni E, Cellini C, Plasmati R, Cangini D, Tacchetti P, et al. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005; 74: 212–216
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Stark R, Day B, Seymour J F, Zeldis J B, Prince H M. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006; 24: 4507–4514
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Marconi M, Malerba L, Mele A, Olivieri A, et al. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. Eur J Haematol 2004; 72: 403–409
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Prince H M. The troublesome toxicity of peripheral neuropathy with thalidomide. Leuk Lymphoma 2006; 47: 2276–2279
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Hayman S, Gertz M A, Dispenzieri A, Lacy M Q, Greipp P R, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319–4323
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Blood E, Vesole D H, Shepard R, Greipp P R. A randomised phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Proc Am Soc Clin Oncol 2004; 23: 558
   Google Scholar
• Rus C, Bazzan M, Palumbo A, Bringhen S, Boccadoro M. Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis [letter]. J Thromb Haemost 2004; 2: 2063–2065
   PubMed Web of Science ®Google Scholar
• Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal A V, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614–1615
   PubMed Web of Science ®Google Scholar
• Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126: 715–721
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030
   PubMed Web of Science ®Google Scholar
• Urbauer E, Kaufmann H, Nösslinger T, Raderer M, Drach J. Thromboembolic events during treatment with thalidomide [letter]. Blood 2002; 99: 4247–4248
   PubMed Web of Science ®Google Scholar
• Honemann D, Prince H M. Myeloma, thalidomide and thrombosis. Leuk Lymphoma 2006; 47: 2273–2275
   PubMed Web of Science ®Google Scholar